SCHEMBL4978635

SCHEMBL4978635

O=C(CCC1CCCC1)N1CCc2c(ncnc2N2CCN(C3CCC3)CC2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
KDM4E B2RXH2 1/20 0.48
MAPT P10636 1/20 0.48
HIF1A Q16665 1/20 0.48
LDHA P00338 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
HRH1 P35367 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
ENPP2 Q13822 1/20 0.39
PARP1 P09874 2/20 0.38
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
LMNA P02545 1/20 0.37
TLR7 Q9NYK1 2/20 0.36
ATM Q13315 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TP53 P04637 1/20 0.36
TLR9 Q9NR96 1/20 0.35
FAAH O00519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4979872 0.90 ADORA2A (0.47) ALDH1A1KDM4EMAPTHIF1AKMT2A
SCHEMBL4982019 0.89 ADORA2A (0.46) ALDH1A1KDM4EMAPTHIF1ALDHA
SCHEMBL4982023 0.88 KCNK3 (0.43) ALDH1A1HIF1AKMT2AMEN1HRH1
SCHEMBL4978085 0.86 KCNK3 (0.40) MAPTKMT2AMEN1HRH1HRH3
SCHEMBL14346771 0.86 TLR7 (0.38) ALDH1A1KDM4EMAPTHIF1AKMT2A
SCHEMBL4974700 0.86 TLR7 (0.40) ALDH1A1HIF1AKMT2AMEN1HRH1
SCHEMBL4976905 0.85 PARP1 (0.37) KDM4EKMT2AHRH1HRH3PARP1
SCHEMBL4977717 0.85 TLR7 (0.39) ALDH1A1KDM4EKMT2AHRH1HRH3
SCHEMBL14346422 0.84 PARP1 (0.36) ALDH1A1KDM4EMAPTHIF1AKMT2A
SCHEMBL4980311 0.83 KDM4E (0.46) KDM4EKMT2AMEN1HRH1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
WO-2007146122-A2 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES HRH3, HRH4, HRH2 ALDH1A1 1142/4885KDM4E 1865/4885MAPT 2301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.